Analysis

COVID-19 A data perspective

COVID-19: A data perspective: Explore key economic trends and social challenges that arise as the COVID-19 situation evolves.

Sort Help
entries

Results

All (54)

All (54) (0 to 10 of 54 results)

  • Articles and reports: 88F0006X2007007
    Description:

    Results from the Survey of Innovation 2003 raised some interesting questions. First, an unexpected one-third of establishments in R&D services were not innovative. According to the guidelines of the Oslo Manual, innovative establishments are those that introduced a new or significantly improved product or process on to the market or into production, within a specified interval. Second, many of these non-innovative establishments indicated that satisfying existing customers was irrelevant to their firms success. This was very different response from all other types of firms.

    This working paper provides a potential explanation of these unexpected results, as well as an overview of available information on establishments in R&D services (NAICS 5417) in the context of professional services generally. The paper assembles descriptive data to show that non-innovative establishments in R&D services differ significantly from other non-innovative establishments and, while not innovative, they are nevertheless highly inventive. It presents some evidence to suggest that they are venture firms (firms relying on infusions of investment capital rather than revenues from sales to sustain their operations) and proposes a specific set of indicators that would facilitate resolution of the nature of firms in this industry group.

    Release date: 2007-12-20

  • Articles and reports: 88F0006X2007006
    Description:

    This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.

    Release date: 2007-12-05

  • Articles and reports: 88-003-X200700210323
    Geography: Canada
    Description:

    Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210324
    Geography: Canada
    Description:

    Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210325
    Geography: Canada
    Description:

    Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210326
    Geography: Canada
    Description:

    Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.

    Release date: 2007-10-09

  • Articles and reports: 88F0006X2007005
    Description:

    This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.

    Release date: 2007-08-31

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10

  • Articles and reports: 88-003-X20060029246
    Geography: Canada
    Description:

    While firms engaged in R&D services are part of the population of firms covered by the Research and Development in Canadian Industry (RDCI) survey and the Biotechnology Use and Development Survey (BUDS), this industry group is not covered by a typical industry survey. This means that there are no industry-specific figures for contribution to GDP or other typical measures of industrial activities and finances. However, data for the industry group are available from the Survey of Innovation 2003, along with other selected professional services. Data from that survey indicate that the establishments in R&D services in physical, engineering and life sciences may be part of a select and highly atypical group of firms and are discussed in this article.

    Release date: 2006-06-27

  • Articles and reports: 88-003-X20050028021
    Geography: Canada
    Description:

    Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.

    Release date: 2005-06-20
Stats in brief (0)

Stats in brief (0) (0 results)

No content available at this time.

Articles and reports (54)

Articles and reports (54) (0 to 10 of 54 results)

  • Articles and reports: 88F0006X2007007
    Description:

    Results from the Survey of Innovation 2003 raised some interesting questions. First, an unexpected one-third of establishments in R&D services were not innovative. According to the guidelines of the Oslo Manual, innovative establishments are those that introduced a new or significantly improved product or process on to the market or into production, within a specified interval. Second, many of these non-innovative establishments indicated that satisfying existing customers was irrelevant to their firms success. This was very different response from all other types of firms.

    This working paper provides a potential explanation of these unexpected results, as well as an overview of available information on establishments in R&D services (NAICS 5417) in the context of professional services generally. The paper assembles descriptive data to show that non-innovative establishments in R&D services differ significantly from other non-innovative establishments and, while not innovative, they are nevertheless highly inventive. It presents some evidence to suggest that they are venture firms (firms relying on infusions of investment capital rather than revenues from sales to sustain their operations) and proposes a specific set of indicators that would facilitate resolution of the nature of firms in this industry group.

    Release date: 2007-12-20

  • Articles and reports: 88F0006X2007006
    Description:

    This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.

    Release date: 2007-12-05

  • Articles and reports: 88-003-X200700210323
    Geography: Canada
    Description:

    Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210324
    Geography: Canada
    Description:

    Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210325
    Geography: Canada
    Description:

    Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210326
    Geography: Canada
    Description:

    Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.

    Release date: 2007-10-09

  • Articles and reports: 88F0006X2007005
    Description:

    This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.

    Release date: 2007-08-31

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10

  • Articles and reports: 88-003-X20060029246
    Geography: Canada
    Description:

    While firms engaged in R&D services are part of the population of firms covered by the Research and Development in Canadian Industry (RDCI) survey and the Biotechnology Use and Development Survey (BUDS), this industry group is not covered by a typical industry survey. This means that there are no industry-specific figures for contribution to GDP or other typical measures of industrial activities and finances. However, data for the industry group are available from the Survey of Innovation 2003, along with other selected professional services. Data from that survey indicate that the establishments in R&D services in physical, engineering and life sciences may be part of a select and highly atypical group of firms and are discussed in this article.

    Release date: 2006-06-27

  • Articles and reports: 88-003-X20050028021
    Geography: Canada
    Description:

    Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.

    Release date: 2005-06-20
Journals and periodicals (0)

Journals and periodicals (0) (0 results)

No content available at this time.

Date modified: